Sleep disruption in children has evolved into a pressing health concern that extends far beyond occasional bedtime struggles, with profound implications for neurodevelopment and family wellbeing. The condition disproportionately affects vulnerable populations, creating cascading effects on academic performance, emotional regulation, and long-term mental health trajectories. Current clinical evidence identifies two primary patterns: behavioral insomnia, often rooted in poor sleep hygiene or environmental factors, and psychophysiological insomnia, characterized by heightened arousal and sleep-related anxiety. Children diagnosed with autism spectrum disorder or ADHD face significantly elevated risks, suggesting neurobiological vulnerabilities that compound traditional sleep challenges. Cognitive behavioral therapy for insomnia has demonstrated superior efficacy compared to pharmaceutical interventions, offering structured approaches to address underlying behavioral and cognitive patterns. While melatonin shows promise specifically for neurodivergent children, the broader pharmacological landscape remains under-researched, leaving clinicians with limited evidence-based options beyond behavioral modifications. This represents a notable gap in pediatric sleep medicine, particularly given the chronic nature of untreated insomnia. The emphasis on early intervention reflects growing recognition that childhood sleep disorders rarely resolve spontaneously and often persist into adolescence and adulthood. For health-conscious families, this analysis underscores the critical importance of addressing sleep concerns proactively rather than assuming children will simply "grow out of" sleep difficulties. The interconnection between quality sleep and cognitive development, immune function, and emotional resilience makes pediatric insomnia a foundational health issue deserving immediate clinical attention.